Humana Inc.

(New York Stock Exchange)
Back to all articles
Somewhat Bearish -25

Q4 Earnings Outperformers: Humana (NYSE:HUM) And The Rest Of The Health Insurance Providers Stocks

AI-generated analysis

πŸ“Š Health insurance providers collectively reported slower Q4 results, with group revenues beating analyst consensus by 0.8% while next-quarter guidance remained neutral.

πŸ“‰ The industry faces headwinds from potential government healthcare reforms, medical cost inflation, and regulatory scrutiny on pricing practices despite tailwinds from an aging population and AI advancements.

πŸ’Ό Humana (NYSE:HUM), with over 80% revenue from federal contracts, reported Q4 revenues of $32.64 billion, an 11.8% year-over-year increase that exceeded expectations by 1.8%.

⚠️ Despite the revenue beat, Humana missed its full-year EPS guidance, leading to a stock price decline of 3.9% since the report and a current trading price of $174.20.

🌱 Clover Health (NASDAQ:CLOV), founded on technology for seniors, saw revenues jump 44.7% year-over-year to $487.7 million, beating estimates by 4.4% and adding 4,577 new customers.

πŸ“‰ Market sentiment remains negative for Clover despite strong operational metrics, with shares dropping 7.3% since reporting and trading at $1.99 per share.

πŸ₯ Molina Healthcare (NYSE:MOH), serving low-income individuals across 21 states, posted Q4 revenues of $11.38 billion, an 8.3% increase that beat analyst expectations by 3.7%.

⚠️ Molina missed full-year revenue and EPS guidance significantly, causing its stock to plunge 19.7% since earnings release and trade at $142.01.

πŸ₯ CVS Health (NYSE:CVS), operating nearly 10,000 pharmacy locations, reported revenues of $105.7 billion, an 8.2% increase surpassing analyst expectations by 2%.

βž– CVS delivered a satisfactory quarter on revenue but missed full-year EPS guidance, leaving its stock price flat at a current trading value of $76.49.

πŸ₯ Elevance Health (NYSE:ELV), formerly Anthem, reported revenues of $49.31 billion with a 9.6% year-over-year increase that fell 1.2% below analyst expectations.

πŸ“‰ The company lost 137,000 customers to end at 45.23 million members and missed both full-year revenue and EPS guidance estimates.

⚠️ Elevance Health shares are down 12.1% since the report, trading currently at $283.95.

πŸ“ˆ Overall, while Q4 top-line growth was generally positive for the sector, misses in EPS guidance have led to a collective market downturn for these health insurance stocks.

Bullish Signals
  • Humana (NYSE:HUM) reported revenues of $32.64 billion, representing an 11.8% year-on-year increase.
  • This revenue figure exceeded analysts' expectations by 1.8%, demonstrating strong top-line performance.
  • The company serves approximately 17 million members with a strong focus on Medicare Advantage plans for seniors.
  • Clover Health (NASDAQ:CLOV) achieved impressive revenue growth of 44.7% year on year.
  • Clover Health pulled off the biggest analyst estimates beat and fastest revenue growth among its peers in the sector.
  • The company added 4,577 new customers to reach a total member base of 113,803.
  • Molina Healthcare (NYSE:MOH) reported revenues of $11.38 billion, up 8.3% year on year.
  • Molina's revenue result exceeded analysts' expectations by 3.7%, showcasing resilient growth despite market headwinds.
  • CVS Health (NYSE:CVS) generated substantial revenues of $105.7 billion, an increase of 8.2% year on year.
  • CVS Health surpassed analysts' expectations by 2%, maintaining a strong revenue trajectory.
  • Elevance Health (NYSE:ELV), formerly Anthem, reported revenues of $49.31 billion, up 9.6% year on year.
  • The health insurance industry benefits from long-term tailwinds including an aging population and increasing demand for personalized healthcare services.
  • Advancements in data analytics are improving cost management capabilities across the sector.
Risk Factors
  • Health insurers face significant risks from continued regulatory scrutiny on pricing practices and potential government-led reforms such as expanded public healthcare options.
  • Inflation in medical costs could add volatility to margins across the health insurance sector.
  • AI adoption in underwriting and claims processing carries ethical concerns, including reinforcing biases and widening disparities in medical care.
  • The broader group of 12 health insurance provider stocks reported a slower Q4, with average share prices down 8.4% since earnings results.
  • Humana missed analysts' full-year EPS guidance estimates despite beating revenue expectations, leading to a 3.9% drop in its stock price to $174.20.
  • Clover Health faces market unhappiness over its results with the stock down 7.3% since reporting, now trading at $1.99.
  • Molina Healthcare significantly missed analysts' full-year revenue and EPS guidance estimates, causing its stock to drop 19.7% to $142.01.
  • CVS Health posted a slight miss of analysts' full-year EPS guidance estimates, despite satisfactory revenue beats.
  • Elevance Health recorded both a significant miss of analysts' full-year EPS guidance and a slight miss of revenue estimates, resulting in a 12.1% stock decline to $283.95.
  • Elevance Health lost 137,000 customers, reducing its total medical member count to 45.23 million.
Full Analysis
As earnings season draws to a close, health insurance provider stocks have experienced a challenging period following recent Q4 reporting. While the sector collectively beat analysts' consensus revenue estimates by 0.8%, share prices have declined significantly, with the average stock dropping 8.4% since the latest results. Analysts note that while upfront premiums provide reliable revenue, profitability remains contingent on accurate risk assessment and medical cost control. The industry faces long-term tailwinds from an aging population and advancements in data analytics, though it contends with headwinds including regulatory scrutiny, potential government-led healthcare reforms, and inflation-driven cost increases. A notable point of debate involves the role of artificial intelligence in underwriting and claims processing versus its potential ethical implications regarding bias. Humana (NYSE:HUM), which derives over 80% of its revenue from federal government contracts and serves approximately 17 million members, reported Q4 revenues of $32.64 billion, an increase of 11.8% year over year that exceeded analyst expectations by 1.8%. Despite this top-line beat, the company missed full-year earnings per share (EPS) guidance, causing its stock to fall 3.9% since reporting and trade at $174.20. Clover Health (NASDAQ:CLOV), founded in 2014 with a focus on technology-driven Medicare Advantage plans, saw its revenues jump 44.7% year over year to $487.7 million, outperforming estimates by 4.4%. The company added 4,577 customers for a total of 113,803 and posted the largest analyst revenue beat among peers, yet its stock remains down 7.3% as it trades at $1.99. Molina Healthcare (NYSE:MOH), serving low-income individuals across 21 states, reported revenues of $11.38 billion, up 8.3% year over year, surpassing analyst expectations by 3.7%. However, the quarter was characterized as softer due to a significant miss of full-year revenue and EPS guidance estimates. Consequently, the stock plummeted 19.7% since reporting and is now trading at $142.01. CVS Health (NYSE:CVS), which operates retail pharmacies and offers health insurance through its Aetna subsidiary, reported revenues of $105.7 billion, an 8.2% year-over-year increase that surpassed analyst estimates by 2%. The stock remained flat at $76.49 after the results were released despite a slight miss in full-year EPS guidance. Elevance Health (NYSE:ELV), formerly Anthem and serving approximately 45.23 million medical members after losing 137,000 customers during the period, reported revenues of $49.31 billion, up 9.6% year over year. The results came in 1.2% below analysts' expectations alongside a significant miss of full-year EPS guidance and a slight revenue miss. This performance led to a 12.1% drop in the stock price, with shares trading at $283.95 following the announcement. Across these major players, while revenues generally outperformed, the broader market reaction has been negative due to guidance misses and concerns over macroeconomic and regulatory pressures affecting future profitability.